CL2022002893A1 - Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias - Google Patents

Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias

Info

Publication number
CL2022002893A1
CL2022002893A1 CL2022002893A CL2022002893A CL2022002893A1 CL 2022002893 A1 CL2022002893 A1 CL 2022002893A1 CL 2022002893 A CL2022002893 A CL 2022002893A CL 2022002893 A CL2022002893 A CL 2022002893A CL 2022002893 A1 CL2022002893 A1 CL 2022002893A1
Authority
CL
Chile
Prior art keywords
compositions
preventing
controlling
methods
mycobacterial infections
Prior art date
Application number
CL2022002893A
Other languages
English (en)
Inventor
Antonio Facciuolo
Philip Griebel
Volker Gerdts
Andrew Potter
Neil Rawlyk
Jeffrey Chen
Elodie Pastural
Manjeet Bains
Michael Trimble
Amy Lee
Robert Hancock
Original Assignee
Univ Saskatchewan
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan, Univ British Columbia filed Critical Univ Saskatchewan
Publication of CL2022002893A1 publication Critical patent/CL2022002893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen antígenos de micobacterias, como MAP y antígenos de M. bovis. Los antígenos se pueden usar en composiciones de subunidades para provocar respuestas inmunitarias con el fin de prevenir y/o controlar infecciones micobacterianas, así como en diagnósticos para detectar mamíferos infectados con micobacterias.
CL2022002893A 2020-04-20 2022-10-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias CL2022002893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063012668P 2020-04-20 2020-04-20

Publications (1)

Publication Number Publication Date
CL2022002893A1 true CL2022002893A1 (es) 2023-06-30

Family

ID=78270853

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002893A CL2022002893A1 (es) 2020-04-20 2022-10-19 Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias

Country Status (8)

Country Link
US (1) US20230218734A1 (es)
EP (1) EP4138894A4 (es)
AU (1) AU2021258911A1 (es)
BR (1) BR112022021258A2 (es)
CA (1) CA3176303A1 (es)
CL (1) CL2022002893A1 (es)
MX (1) MX2022013152A (es)
WO (1) WO2021212215A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972045A1 (en) * 1997-04-02 2000-01-19 Statens Seruminstitut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
EP1029053A1 (en) * 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
WO2007108829A2 (en) * 2005-10-26 2007-09-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US7846420B2 (en) * 2007-04-23 2010-12-07 Greenstein Robert J Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same
EP2271760A2 (en) * 2008-04-29 2011-01-12 Monsanto Technology LLC Genes and uses for plant enhancement
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection
WO2019144139A1 (en) * 2018-01-22 2019-07-25 Oregon State University Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗

Also Published As

Publication number Publication date
WO2021212215A1 (en) 2021-10-28
US20230218734A1 (en) 2023-07-13
CA3176303A1 (en) 2021-10-28
EP4138894A1 (en) 2023-03-01
BR112022021258A2 (pt) 2023-01-17
AU2021258911A1 (en) 2022-11-24
EP4138894A4 (en) 2024-06-26
MX2022013152A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
CL2019002036A1 (es) Anticuerpo contra bcma y su uso.
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
AR105470A1 (es) Métodos para inducir una respuesta inmune
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
CL2019001698A1 (es) Suministro de proteínas basado en bacterias con virulencia atenuada.
WO2014063704A8 (en) M. tuberculosis vaccines
CL2019000402A1 (es) Seguidor solar con acoplamiento cinemático.
BR112017003114A2 (pt) crowdsourcing seletivo de dados relacionados com a localização
MX2018014270A (es) Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
CL2017002554A1 (es) Aparato de elevacion
BR112015019283A2 (pt) composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
DOP2016000223A (es) Plásmidos inmunoestimuladores
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
AR101715A1 (es) Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
CL2022002893A1 (es) Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias
AR094296A1 (es) Composicion inmunogenica que comprende antigenos de mycoplasma
BR112019008653A2 (pt) dispositivo, sistema, e, método de ativação
BR112015012762A2 (pt) antígenos de pseudomonas e combinações de antígenos
CO2021012294A2 (es) Composiciones de lawsonia intracellularis y métodos de uso de las mismas
CL2019000422A1 (es) Vacuna de piojos de mar.
CL2017000555A1 (es) Vacuna multivalente de brucella para la proteccion contra infecciones micobacterianas y metodos para su uso.
BR112018011020A2 (pt) técnicas para emparelhamento comportamental híbrido em um sistema central de contato